Yunkang Group (2325) H1 2025 earnings summary

Executive summary

• H1 revenue was RMB313.2 million, down 17.6% YoY; net loss narrowed 56.1% to RMB55.4 million from RMB126.1 million, aided by lower expenses and impairment charges plus a one-off legal-provision reversal.

• Medical institution alliance testing remained the largest segment at RMB180.3 million, or 57.6% of revenue, and was broadly stable YoY.

Financial highlights

• Gross profit was RMB106.4 million, down 17.0% YoY; gross margin rose to 34.0% from 33.7%, while cost of revenue fell 17.8% to RMB206.8 million.

• Operating loss narrowed to RMB40.3 million from RMB107.5 million; loss before tax was RMB55.4 million versus RMB131.8 million, and net finance costs fell to RMB15.1 million from RMB24.3 million.

• Selling expenses fell 41.0% to RMB53.1 million, administrative expenses fell 21.5% to RMB78.3 million, and net impairment losses declined to RMB8.4 million from RMB52.4 million.

• Basic and diluted loss per share improved to RMB0.09 from RMB0.21.

Outlook and guidance

• Strategy focuses on lean operations, expanding medical institution alliance services, specialty diagnostic innovation, and applying AI to alliance solutions and clinical workflows; no quantitative earnings guidance was stated.

• ZhiYun, developed with Runda Medical, is planned for pilot use with healthcare partners before gradual nationwide rollout, covering pre-diagnosis, diagnosis and post-diagnosis workflows.

• Industry-chain collaboration aims to translate diagnostic innovation into cost-effective clinical solutions; policy support for alliances, grassroots healthcare and precision diagnostics offers opportunities, alongside near-term policy and market challenges.